NCT01040403 - Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

233

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

February 28, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

olodaterol (BI 1744) low

DRUG

low tiotropium bromide

DRUG

olodaterol (BI 1744) high

DRUG

medium tiotropium bromide

DRUG

high tiotropium bromide

DRUG

Placebo

DEVICE

Respimat

Respimat inhaler

Trial Locations (33)

Unknown

1237.18.02004 Boehringer Ingelheim Investigational Site, Vancouver

1237.18.02005 Boehringer Ingelheim Investigational Site, Grimsby

1237.18.02001 Boehringer Ingelheim Investigational Site, Mississauga

1237.18.02008 Boehringer Ingelheim Investigational Site, Toronto

1237.18.02002 Boehringer Ingelheim Investigational Site, Montreal

1237.18.02003 Boehringer Ingelheim Investigational Site, Point Claire

1237.18.02009 Boehringer Ingelheim Investigational Site, Québec

1237.18.02007 Boehringer Ingelheim Investigational Site, Sherbrooke

1237.18.02011 Boehringer Ingelheim Investigational Site, Saskatoon

1237.18.49009 Boehringer Ingelheim Investigational Site, Aschaffenburg

1237.18.49012 Boehringer Ingelheim Investigational Site, Bamberg

1237.18.49005 Boehringer Ingelheim Investigational Site, Berlin

1237.18.49004 Boehringer Ingelheim Investigational Site, Frankfurt

1237.18.49011 Boehringer Ingelheim Investigational Site, Hamburg

1237.18.49010 Boehringer Ingelheim Investigational Site, Koblenz

1237.18.49007 Boehringer Ingelheim Investigational Site, Mannheim

1237.18.49001 Boehringer Ingelheim Investigational Site, Potsdam

1237.18.49006 Boehringer Ingelheim Investigational Site, Rodgau-Dudenhofen

1237.18.49002 Boehringer Ingelheim Investigational Site, Rüdersdorf

1237.18.49003 Boehringer Ingelheim Investigational Site, Weinheim

1237.18.49008 Boehringer Ingelheim Investigational Site, Wiesloch

1237.18.31004 Boehringer Ingelheim Investigational Site, Almelo

1237.18.31006 Boehringer Ingelheim Investigational Site, Amsterdam

1237.18.31008 Boehringer Ingelheim Investigational Site, Eindhoven

1237.18.31001 Boehringer Ingelheim Investigational Site, Groningen

1237.18.31007 Boehringer Ingelheim Investigational Site, Hengelo

1237.18.31005 Boehringer Ingelheim Investigational Site, Hoorn

1237.18.31002 Boehringer Ingelheim Investigational Site, Veldhoven

1237.18.31003 Boehringer Ingelheim Investigational Site, Zutphen

1237.18.46003 Boehringer Ingelheim Investigational Site, Boden

1237.18.46002 Boehringer Ingelheim Investigational Site, Gothenburg

1237.18.46001 Boehringer Ingelheim Investigational Site, Lund

1237.18.46004 Boehringer Ingelheim Investigational Site, Stockholm